| Abstract | From November 1979 to July 1986, 52 patients (27 women and 25 men; median age 52 years) with advanced adrenocortical carcinoma entered a prospective, nonrandomized study evaluating moderate-dose mitotane and doxorubicin hydrochloride (Adriamycin). Thirty-two tumors (62%) were well differentiated and evidence of hormone production was present in 24 patients (46%). Patients with well-differentiated or functional tumors received mitotane, 6 gm daily; patients for whom mitotane failed or those with poorly differentiated, non-hormone-producing tumors received Adriamycin, 60 mg/m2 every 3 weeks. Initially, 36 patients were treated with mitotane and 16 patients with Adriamycin. Eight patients (22%) responded to mitotane and three (19%) responded to Adriamycin. No response was noted in the 15 patients for whom mitotane failed and who then received Adriamycin. Severe toxicity occurred in 36% of patients who received mitotane and in 26% who received Adriamycin. Overall median survival after onset of treatment was 14 months. We conclude that mitotane or Adriamycin used initially can induce tumor regression in about 22% and 19% of selected patients, respectively. However, Adriamycin is ineffective as second-line chemotherapy for patients with well-differentiated or functioning tumors for whom mitotane is ineffective. |
| Authors | R A Decker, P Elson, T F Hogan, D L Citrin, D W Westring, T K Banerjee, K W Gilchrist, J Horton
(Affiliation: Department of Surgery, Marshfield Clinic, Wis. 54449.)
|
| Journal | Surgery
(Surgery)
Vol. 110
Issue 6
Pg. 1006-13
(Dec 1991)
ISSN: 0039-6060 UNITED STATES |
| PMID | 1745969
(Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
| Chemical References |
|
| Topics |
- Adrenal Cortex Neoplasms
(drug therapy, pathology)
- Adult
- Aged
- Carcinoma
(drug therapy, pathology)
- Doxorubicin
(adverse effects, therapeutic use)
- Drug Evaluation
- Female
- Humans
- Male
- Middle Aged
- Mitotane
(adverse effects, therapeutic use)
- Prospective Studies
- Survival Analysis
- Treatment Outcome
|
